American Vanguard (AVD) 10-Q 4 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 25, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,783,029

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Net sales	$ 70,673	$ 69,474
Cost of sales	40,589	41,971
Gross profit	30,084	27,503
Operating expenses	24,951	22,873
Operating income	5,133	4,630
Interest expense, net	298	541
Income before provision for income taxes and loss on equity method investment	4,835	4,089
Income taxes expense	1,380	1,060
Income before loss on equity method investment	3,455	3,029
Loss from equity method investment	42	82
Net income	3,413	2,947
Loss (income) attributable to non-controlling interest	39	(153)
Net income attributable to American Vanguard	$ 3,452	$ 2,794
Earnings per common share—basic	$ 0.12	$ 0.10
Earnings per common share—assuming dilution	$ 0.12	$ 0.10
Weighted average shares outstanding—basic	28,947	28,808
Weighted average shares outstanding—assuming dilution	29,654	29,307

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 3,413	$ 2,947
Comprehensive income:
Foreign currency translation adjustment	757	85
Comprehensive income	4,170	3,032
Loss (income) attributable to non-controlling interest	39	(153)
Comprehensive income attributable to American Vanguard	$ 4,209	$ 2,879

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 10,792	$ 7,869
Receivables:
Trade, net of allowance for doubtful accounts of $112 and $42, respectively	72,758	83,777
Other	3,314	3,429
Total receivables, net	76,072	87,206
Inventories	122,279	120,576
Prepaid expenses	12,461	11,424
Total current assets	221,604	227,075
Property, plant and equipment, net	51,425	50,295
Intangible assets, net of applicable amortization	119,757	121,433
Other assets	29,819	31,153
Total assets	422,605	429,956
Current liabilities:
Current installments of other liabilities	33	26
Accounts payable	21,333	24,358
Deferred revenue	3,454	3,848
Accrued program costs	49,542	42,930
Accrued expenses and other payables	6,586	12,072
Income tax payable	14,633	13,840
Total current liabilities	95,581	97,074
Long-term debt, net	29,993	40,951
Other liabilities, excluding current installments	2,842	2,868
Deferred income tax liabilities	6,714	6,706
Total liabilities	135,130	147,599
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,213,960 shares at March 31, 2017 and 31,819,695 shares at December 31, 2016	3,222	3,183
Additional paid-in capital	73,043	71,699
Accumulated other comprehensive loss	(4,094)	(4,851)
Retained earnings	223,445	220,428
Total stockholders' equity including treasury stock	295,616	290,459
Less treasury stock at cost, 2,450,634 shares at March 31, 2017 and December 31, 2016	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	287,347	282,190
Non-controlling interest	128	167
Total stockholders’ equity	287,475	282,357
Total liabilities and stockholders’ equity	$ 422,605	$ 429,956

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 112	$ 42
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	32,213,960	31,819,695
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2015				$ (3,541)
Foreign currency translation adjustment, net				(1,310)
Balance (in shares) at Dec. 31, 2016	31,819,695	31,819,695				2,450,634
Balance at Dec. 31, 2016	$ 282,357	$ 3,183	$ 71,699	(4,851)	$ 220,428	$ (8,269)	$ 282,190	$ 167
Stocks issued under ESPP (in shares)		16,349
Stocks issued under ESPP	250	$ 2	248				250
Cash dividends on common stock ($0.015 per share)	(435)				(435)		(435)
Foreign currency translation adjustment, net	757			757			757
Stock based compensation	1,080		1,080				1,080
Stock options exercised; grants and vesting of restricted stock units	53	$ 37	16				53
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		377,916
Net income	$ 3,413				3,452		3,452	(39)
Balance (in shares) at Mar. 31, 2017	32,213,960	32,213,960				2,450,634
Balance at Mar. 31, 2017	$ 287,475	$ 3,222	$ 73,043	$ (4,094)	$ 223,445	$ (8,269)	$ 287,347	$ 128

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Mar. 31, 2017$ / shares
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.015

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 3,413	$ 2,947
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	3,939	4,315
Amortization of other long term assets	1,423	1,092
Amortization of discounted liabilities	6	9
Stock-based compensation	1,080	456
Excess tax benefit from exercise of stock options		(35)
Increase in deferred income taxes	8
Loss from equity method investment	42	82
Changes in assets and liabilities associated with operations:
Decrease (increase) in net receivables	11,422	(10,202)
Increase in inventories	(1,366)	(7,938)
Increase in prepaid expenses and other assets	(1,126)	(1,036)
Decrease in income tax receivable/payable, net	793	1,205
(Decrease) increase in accounts payable	(3,025)	13,031
Decrease in deferred revenue	(394)	(1,848)
Increase in other payables and accrued expenses	955	7,512
Net cash provided by operating activities	17,170	9,590
Cash flows from investing activities:
Capital expenditures	(3,080)	(715)
Investment	(300)	(3,283)
Net cash used in investing activities	(3,380)	(3,998)
Cash flows from financing activities:
Payments under line of credit agreement	(27,000)	(14,600)
Borrowings under line of credit agreement	16,000	12,000
Payments on other long-term liabilities		(373)
Tax benefit from exercise of stock options		35
Net payments from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholding)	303	(315)
Payment of cash dividends	(289)
Net cash used in by financing activities	(10,986)	(3,253)
Net increase in cash and cash equivalents	2,804	2,339
Cash and cash equivalents at beginning of period	7,869	5,524
Effect of exchange rate changes on cash and cash equivalents	119	53
Cash and cash equivalents at end of period	$ 10,792	$ 7,916

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	2. Property, plant and equipment at March 31, 2017 and December 31, 2016 consists of the following: March 31, 2017 December 31, 2016 Land $ 2,458 $ 2,458 Buildings and improvements 16,451 15,515 Machinery and equipment 105,018 102,146 Office furniture, fixtures and equipment 5,233 5,016 Automotive equipment 442 387 Construction in progress 5,872 8,047 Total gross value 135,474 133,569 Less accumulated depreciation (84,049 ) (83,274 ) Total net value $ 51,425 $ 50,295 The Company recognized depreciation expense related to property and equipment of $1,950 and $2,254 for the three months ended March 31, 2017 and 2016, respectively. During the three months ended March 31, 2017 and 2016, the Company eliminated from assets and accumulated depreciation $1,175 and $127, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: March 31, 2017 December 31, 2016 Finished products $ 103,440 $ 103,832 Raw materials 18,839 16,744 $ 122,279 $ 120,576 As of March 31, 2017, we believe our inventories are valued at lower of cost or market. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330). Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this new standard effective January 1, 2017. There was no impact on this adoption.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended March 31 2017 2016 Net sales: Insecticides $ 37,942 $ 33,106 Herbicides/soil fumigants/fungicides 20,021 24,685 Other, including plant growth regulators 3,392 3,277 Net sales: 61,355 61,068 Non-crop 9,318 8,406 Total net sales: $ 70,673 $ 69,474 Net sales: US $ 52,244 $ 49,855 International 18,429 19,619 Total net sales: $ 70,673 $ 69,474

Accrued Program Costs

Accrued Program Costs	3 Months Ended
	Mar. 31, 2017
Payables And Accruals [Abstract]
Accrued Program Costs	5. Accrued Program Costs

Cash Dividend

Cash Dividend	3 Months Ended
	Mar. 31, 2017
Cash Dividends [Abstract]
Cash Dividend	6. The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 7, 2017 March 31, 2017 April 14, 2017 $ 0.015 $ 435 December 18, 2016 December 23, 2016 January 6, 2017 $ 0.010 $ 289

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended March 31, 2017 2016 Numerator: Net income attributable to AVD $ 3,452 $ 2,794 Denominator (in thousands): Weighted averages shares outstanding-basic 28,947 28,808 Dilutive effect of stock options and grants 707 499 29,654 29,307 For the three months ended March 31, 2017 and 2016, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Indebtedness	8. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at March 31, 2017 and December 31, 2016. The Company has no short term debt as of March 31, 2017 and December 31, 2016. These are summarized in the following table: Long-term indebtedness ($000's) March 31, 2017 December 31, 2016 Revolving line of credit $ 30,400 $ 41,400 Deferred loan fees (407 ) (449 ) Total indebtedness $ 29,993 $ 40,951 AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, are parties to a credit agreement, dated as of June 17, 2013 (the “Credit Agreement”), with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The Credit Agreement is a senior secured lending facility with a five year term and consisting of a revolving line of credit of $200 million and an accordion feature for up to $100 million. The Credit Agreement includes both AMVAC CV and AMVAC BV as borrowers. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. The senior secured revolving line of credit matures on June 17, 2018. Under the Credit Agreement, the Company has three key covenants (with which it was in compliance throughout the three months ended March 31, 2017). The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. At March 31, 2017, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $119,994, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $65,373 as of March 31, 2016. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has improved, (2) net borrowings, which have decreased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Reclassification	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the March 31, 2017 presentation.

Comprehensive income

Comprehensive income	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Comprehensive income	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month period ended March 31, 2017, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	11. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2017 and 2016. Stock-Based Compensation for the Three months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) March 31, 2017 Incentive Stock Options $ 84 $ 293 0.8 Restricted Stock 656 5,438 2.5 Performance Based Restricted Stock 300 2,385 2.5 Performance Based Options 40 128 0.8 Total $ 1,080 $ 8,244 March 31, 2016 Incentive Stock Options $ 89 $ 746 1.7 Restricted Stock 326 1,462 1.4 Performance Based Restricted Stock 33 441 1.3 Performance Based Options 8 263 1.7 Total $ 456 $ 2,912 Stock Options—During the three months ended March 31, 2017, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 541,905 $ 9.33 $ 7.97 Options exercised (15,000 ) 7.50 — Options forfeited (3,919 ) 11.49 — Balance outstanding, March 31, 2017 522,986 $ 9.37 $ 7.99 Information relating to stock options at March 31, 2017, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 283,350 44 $ 7.5 283,350 $ 7.50 $11.32—$14.49 239,636 89 $ 11.57 34,334 $ 12.07 522,986 $ 9.37 317,684 $ 7.99 The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of March 31, 2017, were as follows: As of March 31, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 522,986 $ 9.37 65 $ 3,783 Expected to Vest 518,897 $ 9.35 65 $ 3,762 Exercisable 317,684 $ 7.99 47 $ 2,734 During the three months ended March 31, 2017 and 2016, the Company recognized stock-based compensation related to stock options of $84 and $89, respectively. As of March 31, 2017 and 2016, the Company had approximately $293 and $746, of unamortized stock-based compensation related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 0.8 and 1.7 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Common stock grants — Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 324,756 $ 14.75 362,841 $ 20.43 Granted 251,475 16.10 — — Vested (10,100 ) 12.95 (127,274 ) 31.29 Forfeited (6,544 ) 15.26 (16,008 ) 23.67 Nonvested shares at March 31 st 559,587 $ 15.38 219,559 $ 14.59 Common stock grants — During the three months ended March 31, 2017, the Company issued a total of 251,475 shares of restricted common stock to employees. The shares will cliff vest after three years of service. The shares granted in 2017 were average fair valued at $16.10 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of restricted shares over the required service period. During the three months ended March 31, 2016, the Company issued a total of 119,402 shares of restricted common stock to employees. The shares will cliff vest after three years of service. The shares granted in 2016 were average fair valued at $15.10 per share. The fair value was determined by using the publicly traded share price as of the date the grant was approved. The Company will recognize as expense the value of restricted shares over the required service period. As the shares were subject to stockholder approval at the time the shares were issued, they were excluded from the table above. During the three months ended March 31, 2017 and 2016, the Company recognized stock-based compensation related to restricted shares of $656 and $326, respectively. As of March 31, 2017 and 2016, the Company had approximately $5,438 and $1,462, respectively, of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.5 and 1.4 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 119,022 $ 14.18 104,403 $ 17.05 Granted 121,194 15.40 — — Forfeited — — (9,395 ) 17.65 Nonvested shares at March 31 st 240,216 $ 14.80 95,008 $ 16.99 Performance Based Shares — During the three months ended March 31, 2017, the Company issued a total of 121,194 performance based shares to employees. The shares granted during the first quarter of 2017 have an average fair value of $15.40. The fair value was determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. During the three months ended March 31, 2016, the Company conditionally granted a total of 52,170 performance based shares that will cliff vest on January 6, 2019 with a measurement period commencing January 1, 2016 and ending December 31, 2018. The shares granted to management during the first quarter of 2016, were subject to stockholder approval to extend the term of the Company’s stock incentive plan. That approval was received at the stockholder meeting on June 8, 2016. At that point the shares were given a fair value of $14.39. The fair value was determined by using publically traded share price on the date that the shareholders approved the grant. Eighty percent of these performance based shares are based upon the financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for recording less than the targeted performance and to increase to a maximum of 200% for achieving in of the targeted performance. As the shares were subject to stockholder approval at the time the shares were issued to management, no expense was recorded during the first quarter of 2016 and the shares were consequently excluded from the table above. As of March 31, 2017, performance based shares related to earnings before income tax (“EBIT”) and net sales have an average fair value of $16.10 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $12.60 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended March 31, 2017 and 2016, the Company recognized stock-based compensation related to performance based shares of $300 and $33, respectively. As of March 31, 2017 and 2016, the Company had approximately $2,385 and $441, respectively, of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.5 and 1.3 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the three months ended March 31, 2017 and 2016, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 82,334 $ 11.49 $ — Options forfeited — — — Balance outstanding, March 31, 2017 82,334 $ 11.49 $ — Information relating to stock options at March 31, 2017 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 82,334 9 $ 11.49 — $ — The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2017 are as follows: As of March 31, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 82,334 $ 11.49 9 $ 421 Expected to Vest 76,986 $ 11.49 9 $ 393 Exercisable — $ — — $ — During the three months ended March 31, 2017 and 2016, the Company recognized stock-based compensation related to performance stock options of $40 and $8, respectively. As of March 31, 2017 and 2016, the Company had approximately $128 and $263, respectively, of unamortized stock-based compensation expenses related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 0.8 and 1.7 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718)

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	12. Legal Proceedings— During the reporting period, there have been no material developments in legal proceedings that were reported in the Company’s Form 10-K for the period ended December 31, 2016, except as described below. Harold Reed v. AMVAC et al Walker v. AMVAC

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance— In November 2016, FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230). In October 2016 FASB issued ASU 2016-16, Income Taxes (Topic 740). In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) In February 2016, FASB issued ASU 2016-02, Leases In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”) — Total Balance, December 31, 2015 $ (3,541 ) FX translation (1,310 ) Balance, December 31, 2016 (4,851 ) FX translation 757 Balance, March 31, 2017 $ (4,094 )

Equity Investment

Equity Investment	3 Months Ended
	Mar. 31, 2017
Tyra Tech Inc
Equity Investment	16. TyraTech Inc. (“TyraTech”) is a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. As of March 31, 2017, the Company’s ownership position in TyraTech was approximately 15.11%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three months ended March 31, 2017, the Company recognized a loss of $42 as a result of the Company’s ownership position in TyraTech. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At March 31, 2017, the carrying value of the Company’s investment in TyraTech was $2,142 and the quoted market value of its shareholding was $1,127 based on the London Stock Exchange, Alternative Investment Market (“AIM”). At March 31, 2017, the Company performed an impairment review of its investment in TyraTech and concluded that the implied decrease in value was not other than temporary and no impairment charge was required.

Cost Method Investment

Cost Method Investment	3 Months Ended
	Mar. 31, 2017
Biological Products For Agriculture
Cost Method Investment	17. In February 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of March 31, 2017, the Company’s ownership position in Bi-PA was 15%. The Company utilizes the cost method of accounting with respect to this investment and will periodically review the investment for possible impairment. There was no impairment on the investment as of March 31, 2017. The investment is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes – Income tax expense was $1,380 for the three months ended March 31, 2017, as compared to $1,060 for the three months ended March 31, 2016. The effective tax rate for the three months ended March 31, 2017 and 2016 was 28.5% and 25.9%, respectively. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The Company currently is undergoing an examination by the Internal Revenue Service (“IRS”) for the tax years ended December 31, 2013 and 2014. While the audit is ongoing, the Company has agreed to a proposed adjustment. As a result, the Company increased deferred tax assets and income taxes payable at December 31, 2016 by $12,598. Furthermore, the Federal tax return for the 2015 tax year is subject to IRS examination. The Company’s state income tax returns are subject to examination for the 2012 through 2015 tax years. On April 3, 2017, the Company paid the IRS $11,580.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at March 31, 2017 and December 31, 2016 consists of the following: March 31, 2017 December 31, 2016 Land $ 2,458 $ 2,458 Buildings and improvements 16,451 15,515 Machinery and equipment 105,018 102,146 Office furniture, fixtures and equipment 5,233 5,016 Automotive equipment 442 387 Construction in progress 5,872 8,047 Total gross value 135,474 133,569 Less accumulated depreciation (84,049 ) (83,274 ) Total net value $ 51,425 $ 50,295

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: March 31, 2017 December 31, 2016 Finished products $ 103,440 $ 103,832 Raw materials 18,839 16,744 $ 122,279 $ 120,576

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended March 31 2017 2016 Net sales: Insecticides $ 37,942 $ 33,106 Herbicides/soil fumigants/fungicides 20,021 24,685 Other, including plant growth regulators 3,392 3,277 Net sales: 61,355 61,068 Non-crop 9,318 8,406 Total net sales: $ 70,673 $ 69,474 Net sales: US $ 52,244 $ 49,855 International 18,429 19,619 Total net sales: $ 70,673 $ 69,474

Cash Dividend (Tables)

Cash Dividend (Tables)	3 Months Ended
	Mar. 31, 2017
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 7, 2017 March 31, 2017 April 14, 2017 $ 0.015 $ 435 December 18, 2016 December 23, 2016 January 6, 2017 $ 0.010 $ 289

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended March 31, 2017 2016 Numerator: Net income attributable to AVD $ 3,452 $ 2,794 Denominator (in thousands): Weighted averages shares outstanding-basic 28,947 28,808 Dilutive effect of stock options and grants 707 499 29,654 29,307

Indebtedness (Tables)

Indebtedness (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Summary of Revolving Line of Credit	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at March 31, 2017 and December 31, 2016. The Company has no short term debt as of March 31, 2017 and December 31, 2016. These are summarized in the following table: Long-term indebtedness ($000's) March 31, 2017 December 31, 2016 Revolving line of credit $ 30,400 $ 41,400 Deferred loan fees (407 ) (449 ) Total indebtedness $ 29,993 $ 40,951

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2017 and 2016. Stock-Based Compensation for the Three months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) March 31, 2017 Incentive Stock Options $ 84 $ 293 0.8 Restricted Stock 656 5,438 2.5 Performance Based Restricted Stock 300 2,385 2.5 Performance Based Options 40 128 0.8 Total $ 1,080 $ 8,244 March 31, 2016 Incentive Stock Options $ 89 $ 746 1.7 Restricted Stock 326 1,462 1.4 Performance Based Restricted Stock 33 441 1.3 Performance Based Options 8 263 1.7 Total $ 456 $ 2,912
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 541,905 $ 9.33 $ 7.97 Options exercised (15,000 ) 7.50 — Options forfeited (3,919 ) 11.49 — Balance outstanding, March 31, 2017 522,986 $ 9.37 $ 7.99
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2017, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 283,350 44 $ 7.5 283,350 $ 7.50 $11.32—$14.49 239,636 89 $ 11.57 34,334 $ 12.07 522,986 $ 9.37 317,684 $ 7.99
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of March 31, 2017, were as follows: As of March 31, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 522,986 $ 9.37 65 $ 3,783 Expected to Vest 518,897 $ 9.35 65 $ 3,762 Exercisable 317,684 $ 7.99 47 $ 2,734
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 82,334 $ 11.49 $ — Options forfeited — — — Balance outstanding, March 31, 2017 82,334 $ 11.49 $ —
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2017 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 82,334 9 $ 11.49 — $ —
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2017 are as follows: As of March 31, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 82,334 $ 11.49 9 $ 421 Expected to Vest 76,986 $ 11.49 9 $ 393 Exercisable — $ — — $ —
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 324,756 $ 14.75 362,841 $ 20.43 Granted 251,475 16.10 — — Vested (10,100 ) 12.95 (127,274 ) 31.29 Forfeited (6,544 ) 15.26 (16,008 ) 23.67 Nonvested shares at March 31 st 559,587 $ 15.38 219,559 $ 14.59
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Shares — Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 119,022 $ 14.18 104,403 $ 17.05 Granted 121,194 15.40 — — Forfeited — — (9,395 ) 17.65 Nonvested shares at March 31 st 240,216 $ 14.80 95,008 $ 16.99

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Income ("AOCI") (Tables)	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2015 $ (3,541 ) FX translation (1,310 ) Balance, December 31, 2016 (4,851 ) FX translation 757 Balance, March 31, 2017 $ (4,094 )

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total gross value	$ 135,474	$ 133,569
Less accumulated depreciation	(84,049)	(83,274)
Total net value	51,425	50,295
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	16,451	15,515
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	105,018	102,146
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	5,233	5,016
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	442	387
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 5,872	$ 8,047

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 1,950	$ 2,254
Elimination of Assets and Accumulated depreciation	$ 1,175	$ 127

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished products	$ 103,440	$ 103,832
Raw materials	18,839	16,744
Total Inventories	$ 122,279	$ 120,576

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net sales
Net sales	$ 70,673	$ 69,474
Insecticides
Net sales
Net sales	37,942	33,106
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	20,021	24,685
Other, Including Plant Growth Regulators
Net sales
Net sales	3,392	3,277
Crop
Net sales
Net sales	61,355	61,068
Non-Crop
Net sales
Net sales	9,318	8,406
US
Net sales
Net sales	52,244	49,855
International
Net sales
Net sales	$ 18,429	$ 19,619

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Mar. 7, 2017	Dec. 18, 2016
Cash dividend record date	Mar. 31, 2017	Dec. 23, 2016
Cash dividend distributed date	Apr. 14, 2017	Jan. 6, 2017
Cash dividend per share	$ 0.015	$ 0.010
Cash dividend paid	$ 435	$ 289

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income attributable to AVD	$ 3,452	$ 2,794
Denominator:
Weighted averages shares outstanding-basic	28,947	28,808
Dilutive effect of stock options and grants	707	499
Weighted average shares outstanding-assuming dilution	29,654	29,307

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Short term debt	$ 0	$ 0
Senior secured credit facility term	5 years
Senior secured credit facility, maturity date	Jun. 17, 2018
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	200,000,000		$ 65,373,000
Revolving Line of Credit | Maximum
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	$ 119,994,000

Summary of Revolving Line of Cr

Summary of Revolving Line of Credit (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Revolving line of credit	$ 30,400	$ 41,400
Deferred loan fees	(407)	(449)
Total indebtedness	$ 29,993	$ 40,951

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,080	$ 456
Unamortized Stock-Based Compensation	8,244	2,912
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 84	$ 89
Remaining Weighted Average Period (years)	9 months 18 days	1 year 8 months 12 days
Unamortized Stock-Based Compensation	$ 293	$ 746
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 656	$ 326
Remaining Weighted Average Period (years)	2 years 6 months	1 year 4 months 24 days
Unamortized Stock-Based Compensation	$ 5,438	$ 1,462
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 300	$ 33
Remaining Weighted Average Period (years)	2 years 6 months	1 year 3 months 18 days
Unamortized Stock-Based Compensation	$ 2,385	$ 441
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 40	$ 8
Remaining Weighted Average Period (years)	9 months 18 days	1 year 8 months 12 days
Unamortized Stock-Based Compensation	$ 128	$ 263

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($)	Jun. 08, 2016	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted		0
Stock-based compensation		$ 1,080,000	$ 456,000
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		40,000	8,000
Nonvested unamortized stock-based compensation expense, value		$ 128,000	$ 263,000
Remaining Weighted Average Period (years)		9 months 18 days	1 year 8 months 12 days
Number of shares granted to employees		0	0
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 84,000	$ 89,000
Nonvested unamortized stock-based compensation expense, value		$ 293,000	$ 746,000
Remaining Weighted Average Period (years)		9 months 18 days	1 year 8 months 12 days
Common Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 656,000	$ 326,000
Remaining Weighted Average Period (years)		2 years 6 months	1 year 4 months 24 days
Number of shares granted to employees		251,475
Number of years of service before cliff vesting		3 years	3 years
Weighted Average Grant-Date Fair Value, Granted		$ 16.10	$ 15.10
Shares issued by equity investee			119,402
Unamortized Stock-Based Compensation		$ 5,438,000	$ 1,462,000
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 300,000	$ 33,000
Remaining Weighted Average Period (years)		2 years 6 months	1 year 3 months 18 days
Number of shares granted to employees		121,194	52,170
Weighted Average Grant-Date Fair Value, Granted	$ 14.39	$ 15.40
Unamortized Stock-Based Compensation		$ 2,385,000	$ 441,000
Targeted performance percentage		200.00%	200.00%
Performance Based Restricted Stock | Subject To Stockholder Approval
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation			$ 0
Performance Based Restricted Stock | Vested on February 8, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date		Feb. 8, 2020	Jan. 6, 2019
Performance Based Restricted Stock | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance		80.00%
Earnings before income tax goal weight, percentage		50.00%
Net sales goal weight, percentage		30.00%
Performance Based Restricted Stock | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income tax goal weight, percentage		20.00%
Performance Based Restricted Stock | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2016 and ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance			80.00%
Earnings before income tax goal weight, percentage			50.00%
Net sales goal weight, percentage			30.00%
Performance Based Restricted Stock | Performance based stock options based upon AVD stock price appreciation over the course of the period commencing January 1, 2016 and ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income tax goal weight, percentage			20.00%
Performance Based Restricted Stock | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2017 and Ending December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted		$ 16.10
Performance Based Restricted Stock | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2017 and Ending December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted		$ 12.60

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	541,905
Incentive Stock Option Plans, Option exercised | shares	(15,000)
Incentive Stock Option Plans, Option forfeited | shares	(3,919)
Incentive Stock Option Plans, Ending balance | shares	522,986
Weighted Average Price Per Share, Beginning balance	$ 9.33
Weighted Average Price Per Share, Option exercised	7.50
Weighted Average Price Per Share, Option forfeited	11.49
Weighted Average Price Per Share, Ending balance	9.37
Exercisable Weighted Average Price Per Share, Beginning balance	7.97
Exercisable Weighted Average Price Per Share, Ending balance	$ 7.99

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	522,986
Outstanding Weighted Average, Exercise Price	$ 9.37	$ 9.33
Exercisable Weighted Average, Shares	317,684
Exercisable Weighted Average, Exercise Price	$ 7.99	$ 7.97
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	283,350
Outstanding Weighted Average, Remaining Life (Months)	44 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Exercisable Weighted Average, Shares	283,350
Exercisable Weighted Average, Exercise Price	$ 7.50
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	239,636
Outstanding Weighted Average, Remaining Life (Months)	89 months
Outstanding Weighted Average, Exercise Price	$ 11.57
Exercisable Weighted Average, Shares	34,334
Exercisable Weighted Average, Exercise Price	$ 12.07

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - Incentive Stock Option Plan $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding | shares	522,986
Number of Shares, Expected to Vest | shares	518,897
Number of Shares, Exercisable | shares	317,684
Weighted Average Exercise Price, Outstanding | $ / shares	$ 9.37
Weighted Average Exercise Price, Expected to Vest | $ / shares	9.35
Weighted Average Exercisable, Exercise Price | $ / shares	$ 7.99
Weighted Average Remaining Life, Outstanding	65 months
Weighted Average Remaining Contractual Life, Expected to Vest	65 months
Weighted Average Remaining Contractual Life, Exercisable	47 months
Intrinsic Value, Outstanding | $	$ 3,783
Intrinsic Value, Expected to Vest | $	3,762
Intrinsic Value, Exercisable | $	$ 2,734

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Common Stock Grants - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	324,756	362,841
Number of Shares, Granted	251,475
Number of Shares, Vested	(10,100)	(127,274)
Number of Shares, Forfeited	(6,544)	(16,008)
Number of Shares, Ending Balance	559,587	219,559
Weighted Average Grant-Date Fair Value, Beginning balance	$ 14.75	$ 20.43
Weighted Average Grant-Date Fair Value, Granted	16.10	15.10
Weighted Average Grant-Date Fair Value, Vested	12.95	31.29
Weighted Average Grant-Date Fair Value, Forfeited	15.26	23.67
Weighted Average Grant-Date Fair Value, Ending balance	$ 15.38	$ 14.59

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Based Restricted Shares - $ / shares	Jun. 08, 2016	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance		119,022	104,403
Number of Shares, Granted		121,194	52,170
Number of Shares, Forfeited			(9,395)
Number of Shares, Ending Balance		240,216	95,008
Weighted Average Grant-Date Fair Value, Beginning balance		$ 14.18	$ 17.05
Weighted Average Grant-Date Fair Value, Granted	$ 14.39	15.40
Weighted Average Grant-Date Fair Value, Forfeited			17.65
Weighted Average Grant-Date Fair Value, Ending balance		$ 14.80	$ 16.99

Summary of Performance option a

Summary of Performance option activity (Detail) - Performance Based Stock Options	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	82,334
Incentive Stock Option Plans, Option forfeited | shares	0
Incentive Stock Option Plans, Ending balance | shares	82,334
Weighted Average Price Per Share, Beginning balance | $ / shares	$ 11.49
Weighted Average Price Per Share, Option forfeited | $ / shares	0
Weighted Average Price Per Share, Ending balance | $ / shares	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares | shares	82,334
Outstanding Weighted Average, Remaining Life (Months)	9 months
Outstanding Weighted Average, Exercise Price | $ / shares	$ 11.49

Performance Option Weighted Ave

Performance Option Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - Performance Incentive Stock Option Plan $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding | shares	82,334
Number of Shares, Expected to Vest | shares	76,986
Weighted Average Exercise Price, Outstanding | $ / shares	$ 11.49
Weighted Average Exercise Price, Expected to Vest | $ / shares	$ 11.49
Weighted Average Remaining Life, Outstanding	9 months
Weighted Average Remaining Contractual Life, Expected to Vest	9 months
Intrinsic Value, Outstanding | $	$ 421
Intrinsic Value, Expected to Vest | $	$ 393

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail) $ in Thousands	Mar. 29, 2016Case	Jan. 31, 2017USD ($)Case
Harold Reed v. AMVAC et al.
Loss Contingencies [Line Items]
Number of lawsuits filed | Case	2
Reed
Loss Contingencies [Line Items]
Loss contingency damages sought, value		$ 250
Jem Holdings
Loss Contingencies [Line Items]
Loss contingency damages sought, value		$ 60
Cross Claims
Loss Contingencies [Line Items]
Number of lawsuits filed | Case		4
Van Giessen Growers, Inc.
Loss Contingencies [Line Items]
Loss contingency estimate of possible loss		$ 400
Chin Coulee Farms
Loss Contingencies [Line Items]
Loss contingency estimate of possible loss		530
Houweling Farms
Loss Contingencies [Line Items]
Loss contingency estimate of possible loss		$ 4,300

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 282,357
Foreign currency translation adjustment	757	$ 85
Balance	287,475		$ 282,357
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(4,851)	$ (3,541)	(3,541)
Foreign currency translation adjustment	757		(1,310)
Balance	$ (4,094)		$ (4,851)

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Equity Method Investments [Line Items]
Gain loss from equity method investment	$ (42)	$ (82)
Tyra Tech Inc
Equity Method Investments [Line Items]
Equity investment ownership position	15.11%
Gain loss from equity method investment	$ (42)
Carrying value of equity investment	2,142
Quoted market value of equity investment	$ 1,127

Cost Method Investment - Additi

Cost Method Investment - Additional Information (Detail) - Bi-PA	3 Months Ended
	Mar. 31, 2017USD ($)
Schedule of Cost-method Investments [Line Items]
Cost method ownership percentage	15.00%
Cost-method Investments, Impairment	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 03, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Taxes [Line Items]
Income taxes expense		$ 1,380	$ 1,060
Effective tax rate		28.50%	25.90%
State and Local Jurisdiction | Minimum
Income Taxes [Line Items]
Income Tax Examination Period		2,012
State and Local Jurisdiction | Maximum
Income Taxes [Line Items]
Income Tax Examination Period		2,015
Deferred Tax Assets And Income Taxes Payable
Income Taxes [Line Items]
Prior period reclassification adjustment				$ 12,598
Internal Revenue Service | Subsequent Event
Income Taxes [Line Items]
Amount paid to IRS	$ 11,580